Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease portfolio Omeros is eligible to receive 340 million US dollars in ...
Novo Nordisk licensed a clinical-stage MASP-3 inhibitor from Omeros. Omeros is eligible to receive $340 million upfront, royalties, and up to $2.1 billion in milestone payments. Omeros' cash balance ...
SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results